Zhi Hong Chen
Director/Board Member at Shanghai Neutan Pharmaceutical Co., Ltd.
Profile
Currently, Zhi Hong Chen is General Manager & Director at Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
Zhi Hong Chen active positions
Companies | Position | Start |
---|---|---|
Shanghai Neutan Pharmaceutical Co., Ltd.
Shanghai Neutan Pharmaceutical Co., Ltd. BiotechnologyHealth Technology Shanghai Neutan Pharmaceutical Co., Ltd. provides synthetic chemistry and customization services. Shanghai Neutan Pharmaceutical Co. is a national high-tech enterprise and a one-stop full-process innovative drug CDMO platform. The company is based in Shanghai, China. The Chinese company has established a complete quality assurance system that complies with domestic and international GMP standards. The company offers high-quality CMC, clinical samples, and commercial products. The company's business scope includes pre-clinical CRO, new drug discovery FTE, CMC, new drug discovery FFS, CXO, etc. The company was founded in 2019 by Xue Jun Liu, and the CEO is Xiao Dong Chen. | Director/Board Member | - |
Former positions of Zhi Hong Chen
Companies | Position | End |
---|---|---|
ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD | Chief Executive Officer | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD | Health Technology |
Private companies | 1 |
---|---|
Shanghai Neutan Pharmaceutical Co., Ltd.
Shanghai Neutan Pharmaceutical Co., Ltd. BiotechnologyHealth Technology Shanghai Neutan Pharmaceutical Co., Ltd. provides synthetic chemistry and customization services. Shanghai Neutan Pharmaceutical Co. is a national high-tech enterprise and a one-stop full-process innovative drug CDMO platform. The company is based in Shanghai, China. The Chinese company has established a complete quality assurance system that complies with domestic and international GMP standards. The company offers high-quality CMC, clinical samples, and commercial products. The company's business scope includes pre-clinical CRO, new drug discovery FTE, CMC, new drug discovery FFS, CXO, etc. The company was founded in 2019 by Xue Jun Liu, and the CEO is Xiao Dong Chen. | Health Technology |
- Stock Market
- Insiders
- Zhi Hong Chen